• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies

tetano

Editor, Senior Moderator
J Infect Public Health


. 2022 Nov 19;16(1):4-14.
doi: 10.1016/j.jiph.2022.11.024. Online ahead of print.
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies


Kuldeep Dhama[SUP] 1 [/SUP], Firzan Nainu[SUP] 2 [/SUP], Andri Frediansyah[SUP] 3 [/SUP], Mohd Iqbal Yatoo[SUP] 4 [/SUP], Ranjan K Mohapatra[SUP] 5 [/SUP], Sandip Chakraborty[SUP] 6 [/SUP], Hao Zhou[SUP] 7 [/SUP], Md Rabiul Islam[SUP] 8 [/SUP], Sukamto S Mamada[SUP] 2 [/SUP], Hendrix Indra Kusuma[SUP] 9 [/SUP], Ali A Rabaan[SUP] 10 [/SUP], Saad Alhumaid[SUP] 11 [/SUP], Abbas Al Mutair[SUP] 12 [/SUP], Muhammad Iqhrammullah[SUP] 13 [/SUP], Jaffar A Al-Tawfiq[SUP] 14 [/SUP], Mohammed Al Mohaini[SUP] 15 [/SUP], Abdulkhaliq J Alsalman[SUP] 16 [/SUP], Hardeep Singh Tuli[SUP] 17 [/SUP], Chiranjib Chakraborty[SUP] 18 [/SUP], Harapan Harapan[SUP] 19 [/SUP]



Affiliations

Abstract

Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves of coronavirus disease 2019 (COVID-19) pandemic. Depending on the extent of genomic variations, mutations and adaptation, few of the variants gain the ability to spread quickly across many countries, acquire higher virulency and ability to cause severe disease, morbidity and mortality. These variants have been implicated in lessening the efficacy of the current COVID-19 vaccines and immunotherapies resulting in break-through viral infections in vaccinated individuals and recovered patients. Altogether, these could hinder the protective herd immunity to be achieved through the ongoing progressive COVID-19 vaccination. Currently, the only variant of interest of SARS-CoV-2 is Omicron that was first identified in South Africa. In this review, we present the overview on the emerging SARS-CoV-2 variants with a special focus on the Omicron variant, its lineages and hybrid variants. We discuss the hypotheses of the origin, genetic change and underlying molecular mechanism behind higher transmissibility and immune escape of Omicron variant. Major concerns related to Omicron including the efficacy of the current available immunotherapeutics and vaccines, transmissibility, disease severity, and mortality are discussed. In the last part, challenges and strategies to counter Omicron variant, its lineages and hybrid variants amid the ongoing COVID-19 pandemic are presented.

Keywords: COVID-19; Emerging variance; Omicron; SARS-CoV-2; Variant of concern.
 
Back
Top Bottom